China is Asia’s number one biopharma cluster, according to a ranking system devised by Genetic Engineering & Biotechnology News (see article). The country won the top spot because it led all other countries in biomedical R&D spending ($160 billion out of $243 billion in all of Asia), the number of life science companies (7,500 last year), the total number of industry jobs (over 250,000), and venture capital investment ($74 million to five companies). China was second to Japan in IPOs ($2.1 billion raised by 14 companies since 2010) while its 9,302 biotech/pharma patents (apparently counted from 1970 to the present) were in third place overall.

See more at: